top of page

Parker Institute for Cancer Immunotherapy's John Connolly on what he is seeing at #SITC23

John Connolly describes trends he is seeing in cell therapy, bi-specific engagers, myeloid checkpoint targets, and combinations.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page